Cargando…
Chemical acylation of an acquired serine suppresses oncogenic signaling of K-Ras(G12S)
Drugs that directly impede the function of driver oncogenes offer exceptional efficacy and a therapeutic window. The recently approved mutant selective small-molecule cysteine-reactive covalent inhibitor of the G12C mutant of K-Ras, sotorasib, provides a case in point. KRAS is the most frequently mu...
Autores principales: | Zhang, Ziyang, Guiley, Keelan Z., Shokat, Kevan M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group US
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9596369/ https://www.ncbi.nlm.nih.gov/pubmed/35864332 http://dx.doi.org/10.1038/s41589-022-01065-9 |
Ejemplares similares
-
Chemoselective Covalent
Modification of K-Ras(G12R)
with a Small Molecule Electrophile
por: Zhang, Ziyang, et al.
Publicado: (2022) -
A Small Molecule Reacts with the p53 Somatic Mutant Y220C to Rescue Wild-type Thermal Stability
por: Guiley, Keelan Z., et al.
Publicado: (2023) -
GTP-State-Selective Cyclic Peptide Ligands of K-Ras(G12D)
Block Its Interaction with Raf
por: Zhang, Ziyang, et al.
Publicado: (2020) -
A covalent inhibitor of K-Ras(G12C) induces MHC-I presentation of haptenated peptide neoepitopes targetable by immunotherapy
por: Zhang, Ziyang, et al.
Publicado: (2022) -
Oncogenic G12D mutation alters local conformations and dynamics of K-Ras
por: Vatansever, Sezen, et al.
Publicado: (2019)